Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Sees Significant Decline in Short Interest

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) saw a significant drop in short interest during the month of February. As of February 27th, there was short interest totaling 14,323 shares, a drop of 56.8% from the February 12th total of 33,185 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average daily trading volume, of 31,057 shares, the days-to-cover ratio is currently 0.5 days. Based on an average daily trading volume, of 31,057 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.3% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on NEUP shares. Wall Street Zen downgraded shares of Neuphoria Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, November 23rd. Zacks Research raised shares of Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. HC Wainwright cut their price target on shares of Neuphoria Therapeutics from $21.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, December 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Neuphoria Therapeutics has a consensus rating of “Hold” and an average price target of $21.00.

Institutional Investors Weigh In On Neuphoria Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NEUP. Geode Capital Management LLC boosted its position in Neuphoria Therapeutics by 33.3% in the 4th quarter. Geode Capital Management LLC now owns 17,303 shares of the company’s stock valued at $67,000 after buying an additional 4,325 shares during the period. Persistent Asset Partners Ltd purchased a new position in shares of Neuphoria Therapeutics during the third quarter worth approximately $58,000. Commonwealth Equity Services LLC bought a new stake in shares of Neuphoria Therapeutics during the fourth quarter valued at approximately $43,000. XTX Topco Ltd bought a new stake in shares of Neuphoria Therapeutics during the fourth quarter valued at approximately $47,000. Finally, Boothbay Fund Management LLC purchased a new stake in shares of Neuphoria Therapeutics in the fourth quarter valued at approximately $54,000. Institutional investors own 15.90% of the company’s stock.

Neuphoria Therapeutics Stock Down 4.0%

NEUP traded down $0.19 during trading hours on Friday, reaching $4.54. 117,207 shares of the company’s stock traded hands, compared to its average volume of 53,413. The firm has a 50-day moving average price of $4.19 and a 200 day moving average price of $6.85. The firm has a market capitalization of $24.47 million, a PE ratio of -1.03 and a beta of 0.50. Neuphoria Therapeutics has a 52-week low of $3.64 and a 52-week high of $21.40.

Neuphoria Therapeutics (NASDAQ:NEUP) last released its earnings results on Friday, February 13th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.21). Equities analysts predict that Neuphoria Therapeutics will post -1.56 EPS for the current fiscal year.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.